INT98708

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 2001
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 13
Total Number 13
Disease Relevance 7.47
Pain Relevance 0.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (KRAS) mitochondrion (KRAS) plasma membrane (KRAS)
GTPase activity (KRAS)
Anatomy Link Frequency
colon 1
proximal 1
KRAS (Homo sapiens)
Pain Link Frequency Relevance Heat
Chronic pancreatitis 1 99.96 Very High Very High Very High
tolerance 2 95.92 Very High Very High Very High
aspirin 2 92.16 High High
cINOD 3 90.96 High High
Multiple sclerosis 1 53.12 Quite High
chemokine 106 50.00 Quite Low
alcohol 1 32.64 Quite Low
Inflammation 15 5.84 Low Low
cytokine 15 5.00 Very Low Very Low Very Low
antagonist 11 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Colon Cancer 89 100.00 Very High Very High Very High
Hepatitis C Virus Infection 344 99.98 Very High Very High Very High
Pancreatitis 2 99.96 Very High Very High Very High
Pancreatic Cancer 7 99.84 Very High Very High Very High
Ovarian Cancer 85 99.76 Very High Very High Very High
Cancer 300 99.40 Very High Very High Very High
Microsatellite Instability 9 95.92 Very High Very High Very High
Nicotine Addiction 29 94.24 High High
Bronchiolo-alveolar Adenocarcinoma 5 88.80 High High
Infection 45 87.04 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In this study we evaluate the association between previously identified risk factors for colon cancer and Kirsten-ras (Ki-ras) mutations in tumors.
Ki-ras Binding (association) of in colon associated with cancer and colon cancer
1) Confidence 0.47 Published 2001 Journal Mutat. Res. Section Abstract Doc Link 11600135 Disease Relevance 0.81 Pain Relevance 0.08
Participants with Ki-ras mutations were more likely to have proximal rather than distal tumors.
Ki-ras Binding (Participants) of in proximal associated with cancer
2) Confidence 0.36 Published 2001 Journal Mutat. Res. Section Abstract Doc Link 11600135 Disease Relevance 1.03 Pain Relevance 0.14
For example, the NS3 serine protease (Lamarre et al 2003) and the NS5B RNA dependent RNA polymerase (Lesburg et al 1999) have emerged as potential targets for antiviral therapies.
NS3 Binding (emerged) of
3) Confidence 0.36 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621394 Disease Relevance 0.44 Pain Relevance 0
Recent retrospective data from several independent studies have shown a very negative association between KRAS exon 1 mutations and cetuximab response in mCRC patients.
KRAS Neg (negative) Binding (association) of
4) Confidence 0.32 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2432064 Disease Relevance 0.28 Pain Relevance 0
Once again, KRAS was noted in approximately 30% of patients and was associated with resistance to cetuximab or panitumumab (P = 0.011).
KRAS Binding (associated) of
5) Confidence 0.29 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886332 Disease Relevance 0.66 Pain Relevance 0
In a small study with only 30 mCRC patients, KRAS mutations were strongly associated with lack of response to cetuximab and with a shorter median OS.69 These preliminary data were subsequently confirmed in a larger series of 114 patients.38 No patient with KRAS mutations obtained response to therapy in contrast to 44% of patients with KRAS wild-type.
KRAS Binding (associated) of
6) Confidence 0.28 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886318 Disease Relevance 0.35 Pain Relevance 0
Other molecular alterations such as KRAS and BRAF mutations do not seem to be associated with PPARG methylation, while a correlation with the microsatellite instability status was found (Figure S1) [10].
KRAS Binding (alterations) of associated with microsatellite instability
7) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997072 Disease Relevance 0.86 Pain Relevance 0
, FGF1, MYC, EGFR, KRAS, HER2, and AKT2, have been also associated with ovarian cancer [56].
KRAS Binding (associated) of associated with ovarian cancer
8) Confidence 0.25 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2798669 Disease Relevance 1.11 Pain Relevance 0
The recent TRUST open access erlotinib study in Europe also showed the KRAS was associated with decreased survival, though without statistical significance (Schneider et al 2007).
KRAS Binding (associated) of
9) Confidence 0.20 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721286 Disease Relevance 0.44 Pain Relevance 0
This indicates that the differences observed among farm animals (either selected or not) are comparable to the differences observed within one single natural population, and that S and NS lineages are closely related, with their haplotypes intermixed within one clade.


NS Binding (lineages) of
10) Confidence 0.14 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1858698 Disease Relevance 0 Pain Relevance 0
and HFAs were fixed, permeabilized and immuno-labelled with mouse anti-HCV core (clone 11-B3, GeneTex, Irvine, CA) or mouse anti-HCV NS3 (ab65407, Abcam, Cambridge, MA) and rabbit anti-ionized calcium binding adaptor molecule 1 (Iba-1, Wako Chemicals, Neuss, Germany) in HFµ?
NS3 Binding (binding) of associated with hepatitis c virus infection
11) Confidence 0.12 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2943470 Disease Relevance 0.99 Pain Relevance 0.03
Chronic pancreatitis, K-ras oncogene mutations, and the subsequent generation of reactive oxygen species (ROS) appear to be linked to pancreatic cancer.
K-ras oncogene Binding (linked) of associated with pancreatic cancer and chronic pancreatitis
12) Confidence 0.10 Published 2003 Journal Cancer Res. Section Abstract Doc Link 12649190 Disease Relevance 0.49 Pain Relevance 0.10
The reduced strength of the association of NS3 with treatment outcome compared to the day 28 response may be due to patient variables (such as drug tolerance) influencing the outcome more over the longer time period, and/or that the treatment outcome associations may be influenced by both interferon ?
NS3 Binding (association) of associated with tolerance
13) Confidence 0.06 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2815788 Disease Relevance 0 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox